How to Safely Handle Your Antibody Drug Conjugate
ADCs have huge potential in treating challenging diseases such as cancer. However, it is essential that all necessary equipment, steps, and precautions are in place to en¬sure their safe handling.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1996 entries already.
Entries by Thomas Gabrielczyk
CSL Behring files for MAA of haemophilia B gene therapy
CSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe.
Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services
Sino Biological, a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), which provides biological research reagents and related technical is pleased to announce a CRO services partnership with Ainnocence, Inc. of San Jose, California.
Argenx SE to raise €637m
Dutch autoimmunity specialist Argenx SE has raised $700m to prepare commercialisation of subcutanous efgartigimod as treatment for generalized myasthenia gravis.
Recombinant production
Sino Biological specializes in recombinant production of antibodies and proteins. The company routinely conducts high-throughput projects of up to 1,000 per batch. Sino Biological’s manufacturing facility can also handle large-scale production at gram level.
Bayer invests into synthetic TCRs for cell therapy
TCR-T cell therapy specialist Affini-T Therapeutics Inc. (Seattle, Boston) has raised $175m Series A fnancing co-Led by Vida Ventures and Leaps by Bayer
Bavarian Nordic bags $225m for licence to RSV vaccine
Bavarian Nordic is to receive up to US$225 and double-digit royalties for granting exclusive Chinese commercialisation rights for MVA-BN® RSV to Nuance Pharma.
RTSM benefits: configuration versus customisation
In the 1990s, the first clinical IVR systems (Interactive Voice Response Systems) were developed in order to randomise patients over the phone, and later, to dispense drug and resupply sites as well.
Switzerland paves the way for genome editing
Switzerland is keeping its moratorium on GMO cultivation until 2025, but paving the way for exceptions in precision breeding.
Gilde Healthcare Private Equity IV launches €517m
Gilde Healthcare Private Equity IV (GHPE IV) has closed at €517m for investments in proifitable healthcare companies in the lower mid-market in North-west Europe.